DIADIA0.43%
SPYSPY0.06%
QQQQQQ0.54%
Trending
Top trending tickerAPLDAPLD0.40%
NVDANVDA5.18%
CAPRCAPR64.49%
ETHETH2.98%
AMKRAMKR12.56%
XRPXRP4.21%
MPLTMPLT72.92%
CLSCLS12.85%
VCXVCX31.05%
DOTDOT8.03%
Top trending tickerAPLDAPLD0.40%
NVDANVDA5.18%
CAPRCAPR64.49%
ETHETH2.98%
AMKRAMKR12.56%
XRPXRP4.21%
MPLTMPLT72.92%
CLSCLS12.85%
VCXVCX31.05%
DOTDOT8.03%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolMPLTnews
Exchange: NASDAQ·Updated 08:02 PM EDT
MPLT logo

MPLTMapLight Therapeutics Inc.

$9.90
$26.66
(72.91%)
Today
Closed $9.91
$0.005
(0.05%)
Overnight
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose News·MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
EarningsAug 13
Mkt Cap$1.56B
Vol8.15M
News
all
press releases
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday.
Stocktwits
More News
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.read more...
Benzinga
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MapLight Therapeutics, Inc. (MapLight or the Company) (NASDAQ: MPLT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
Futures Jump As Brent Tumbles Below $90 On Fresh Round Of Iran Ceasefire Optimism
Futures Jump As Brent Tumbles Below $90 On Fresh Round Of Iran Ceasefire Optimism A sharp drop in oil prices prompted by a quieter weekend for geopolitics and a pause in?MidEast hostilities also sparked a drop in bond yields and the USD. A?powerful relief rally in stocks and bonds...
Zero Hedge
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout...
Yahoo! Finance: News
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.read more...
Benzinga
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by HC Wainwright
HC Wainwright raised shares of Maplight Therapeutics to a "strong-buy" rating in a research report on Monday...
MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 5.5% - Here's What Happened
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 5.5% - Here's What Happened...
MarketBeat
Jonathan Gillis Sells 51,900 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) insider Jonathan Gillis sold 51,900 shares of Maplight Therapeutics stock in a transaction on Monday, April 27th. The stock was sold at an...
MarketBeat
Anatol Kreitzer Sells 45,422 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) insider Anatol Kreitzer sold 45,422 shares of the company's stock in a transaction that occurred on Monday, April 27th. The stock was sold...
MarketBeat
<
1
2
>

Advertisement|Remove ads.

Advertisement|Remove ads.